Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis Changhui Zhou et al, 2024, Frontiers in Immunology CrossRef
Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review Raja Nur Firzanah Syaza Raja Sharin et al, 2022, BioMed Research International CrossRef
Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia Pieralessandro Lasalvia et al, 2021, Expert Review of Pharmacoeconomics & Outcomes Research CrossRef
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases Bharati Shriyan et al, 2020, European Journal of Clinical Pharmacology CrossRef
Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China Haijing Guan et al, 2022, Frontiers in Oncology CrossRef
A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation
Jie Zhao et al, 2020, Cancer Management and Research CrossRef
FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma Zeyu Zhang et al, 2021, Frontiers in Pharmacology CrossRef